Fig. 1: Generation of mRNA-based vaccine. | Nature Communications

Fig. 1: Generation of mRNA-based vaccine.

From: A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

Fig. 1

A The structure of LASV particle. B LASV L (green and yellow) and S (purple and multi-color for the GPC) segments. C SDS PAGE gel image of in vitro transcribed prefusion and wild-type LASC GPC vaccine constructs. This was run once. D Animal study outline: schedule for two doses of vaccine, challenge, and end of study. Each group included 5 animals, for a total of 25 animals in the study. The animals were 4–6 weeks old and had a starting weight of 350–400 g. The control group received two doses of sterile phosphate-buffered saline. Graphics were generated by N. Lloyd with Biorender.com and Microsoft PowerPoint.

Back to article page